---
title: "UBS: Positive Clinical Data for HENGRUI PHARMA 's Weight-loss Drug HRS-7535; Attractive Valuation, Reiterates Buy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292157476.md"
description: "UBS reported positive Phase III clinical data for Hengrui Pharma's weight-loss drug HRS-7535, which met its primary endpoint with a 9.8% body weight reduction at 180mg dosage. The broker anticipates an NDA submission in China this year and forecasts RMB5.9 billion in GLP-1 sales by 2035. UBS reiterated a Buy rating on Hengrui Pharmawith a target price of HKD97.4, citing attractive valuation and successful diabetes trial endpoints."
datetime: "2026-07-09T06:36:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292157476.md)
  - [en](https://longbridge.com/en/news/292157476.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292157476.md)
generator: "portal-rs"
---

# UBS: Positive Clinical Data for HENGRUI PHARMA 's Weight-loss Drug HRS-7535; Attractive Valuation, Reiterates Buy

UBS published a report stating that HENGRUI PHARMA (01276.HK) -0.300 (-0.508%) Short selling $8.97M; Ratio 13.214% 's Phase III clinical trial for weight-loss drug HRS-7535 achieved its primary endpoint, and the company expects to submit a New Drug Application (NDA) in China within this year.

The broker believes the clinical data performance of HRS-7535 was positive. As of the end of week 44, the 180mg once-daily dosage group recorded a 9.8% reduction in body weight, with no sign of a plateau in weight-loss efficacy, while the drug also demonstrated good tolerability. The broker forecasts that HENGRUI PHARMA's GLP-1 product portfolio could achieve sales of RMB5.9 billion in the China market by 2035. UBS noted that the company's two domestic Phase III clinical trials targeting type 2 diabetes have also successfully achieved their primary endpoints. UBS maintained the Buy rating on HENGRUI PHARMA, with an H-share TP of HKD97.4.(da/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-07-09 12:25.)

### Related Stocks

- [600276.CN](https://longbridge.com/en/quote/600276.CN.md)
- [01276.HK](https://longbridge.com/en/quote/01276.HK.md)
- [UBS.US](https://longbridge.com/en/quote/UBS.US.md)

## Related News & Research

- [HENGRUI PHARMA  1H26 Net Profit Rises 0.3% YoY to RMB4.465 Billion; Shares Now Down Over 7%](https://longbridge.com/en/news/296422700.md)
- [Shein targets Hong Kong market debut on September 1, sources say](https://longbridge.com/en/news/296562492.md)
- [Hengrui Pharma launches RMB 1 billion-RMB 2 billion A-share buyback, caps price at RMB 81.78](https://longbridge.com/en/news/296368941.md)
- [Hengrui Pharma Advances 2026 Employee Stock Ownership Plan Using Existing A Shares](https://longbridge.com/en/news/296370263.md)
- [SHEIN Reportedly Earmarks At Least USD400M for Cornerstone Investors in HK IPO; TENCENT Said to Be Weighing Participation](https://longbridge.com/en/news/296455585.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**